Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Martin, 2011, Mechanisms of chemical-induced innate immunity in allergic contact dermatitis, Allergy, 66, 1152, 10.1111/j.1398-9995.2011.02652.x
Kaplan, 2012, Early immune events in the induction of allergic contact dermatitis, Nat Rev Immunol, 12, 114, 10.1038/nri3150
Karsak, 2007, Attenuation of allergic contact dermatitis through the endocannabinoid system, Science, 316, 1494, 10.1126/science.1142265
Petrosino, 2010, Protective role of palmitoylethanolamide in contact allergic dermatitis, Allergy, 65, 698, 10.1111/j.1398-9995.2009.02254.x
Klein, 2005, Cannabinoid-based drugs as anti-inflammatory therapeutics, Nat Rev Immunol, 5, 400, 10.1038/nri1602
Nagarkatti, 2009, Cannabinoids as novel anti-inflammatory drugs, Future Med Chem, 1, 1333, 10.4155/fmc.09.93
Kupczyk, 2009, Cannabinoid system in the skin - a possible target for future therapies in dermatology, Exp Dermatol, 18, 669, 10.1111/j.1600-0625.2009.00923.x
Buckley, 2000, Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor, Eur J Pharmacol, 396, 141, 10.1016/S0014-2999(00)00211-9
Oka, 2006, Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol, Eur J Pharmacol, 538, 154, 10.1016/j.ejphar.2006.03.021
Maccarrone, 2003, The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase, J Biol Chem, 278, 33896, 10.1074/jbc.M303994200
Albanesi, 2010, Keratinocytes in allergic skin diseases, Curr Opin Allergy Clin Immunol, 10, 452, 10.1097/ACI.0b013e32833e08ae
Braun, 2011, Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors, Immunobiology, 216, 466, 10.1016/j.imbio.2010.09.004
Klein, 1985, The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses, J Immunopharmacol, 7, 451, 10.3109/08923978509026487
Klein, 2000, The cannabinoid system and cytokine network, Proc Soc Exp Biol Med, 225, 1, 10.1046/j.1525-1373.2000.22501.x
Puffenbarger, 2000, Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells, Glia, 29, 58, 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.0.CO;2-W
Leonti, 2010, Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin, Biochem Pharmacol, 79, 1815, 10.1016/j.bcp.2010.02.015
Wilkinson, 2007, Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis, J Dermatol Sci, 45, 87, 10.1016/j.jdermsci.2006.10.009
Bloom, 1997, Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes, Neurochem Res, 22, 563, 10.1023/A:1022413901857
Zhu, 1998, Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1, J Pharmacol Exp Ther, 286, 1103
Derocq, 1995, Cannabinoids enhance human B-cell growth at low nanomolar concentrations, FEBS Lett, 369, 177, 10.1016/0014-5793(95)00746-V
Denda, 2011, Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes, Adv Exp Med Biol, 704, 847, 10.1007/978-94-007-0265-3_44
Jordt, 2004, Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1, Nature, 427, 260, 10.1038/nature02282
Atoyan, 2009, Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin, J Invest Dermatol, 129, 2312, 10.1038/jid.2009.58
Perez-Gomez, 2012, The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas, Oncogene, 10
Begg, 2005, Evidence for novel cannabinoid receptors, Pharmacol Ther, 106, 133, 10.1016/j.pharmthera.2004.11.005
Ross, 2009, The enigmatic pharmacology of GPR55, Trends Pharmacol Sci, 30, 156, 10.1016/j.tips.2008.12.004
O'Sullivan, 2010, Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease, Immunobiology, 215, 611, 10.1016/j.imbio.2009.09.007
Stander, 2006, Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus, Hautarzt, 57, 801